The Effect of Inflammatory Reactions on Antibody Unresponsiveness to Hepatitis B Vaccine in Hemodialysis Patients

Background and aims: in this study, the effect of infections and inflammation developed during hepatitis b vaccinationprogram on antibody response in hemodialysis (hd) patients was evaluated.methods: in total, 94 patients who had hepatitis b surface antigen (hbsag) (-), antibody to hepatitis b surface (antihbs)(-), antibody against hepatitis b core immunoglobulin g (antihbcigg) (-) (group a) and who were previously vaccinatedbut having antibody titer levels lower than 10 miu/ml (group b), on maintenance hd program were included in thisstudy. in group a, 40 ij.9 intramuscular vaccine on 0, 1, 2 and 6 months and in group b, 40 ij.9 of intramuscular boosterdose vaccine were administered. antibody titer of 10 miu/ml was considered as positive. group a was then dividedinto two subgroups with respect to antibody response (group al and group a2).results: eighty-one patients completed the study (group a; n=64, mean age=42.3±11.4 years; group b: n=17, meanage=53.6±10.6 years). in group a, antibody response was positive in 82.8% (group ai), negative in 17.2% (group a2)and it was positive in 100% of group b. inflammatory parameters, nutritional and demographic features were foundsimilarly in all groups. throughout the study, infections developed most frequently in group a.conclusions: we concluded that acute infections and inflammations developed in patients vaccinated according tovaccination schedule recommended for hbv prophylaxis during hd treatment does not affect antibody response andacute phase reactants are not indicators for negative antibody response.